Rodrigues Mosar Corrêa, Morais José Athayde Vasconcelos, Ganassin Rayane, Oliveira Giulia Rosa Tavares, Costa Fabiana Chagas, Morais Amanda Alencar Cabral, Silveira Ariane Pandolfo, Silva Victor Carlos Mello, Longo João Paulo Figueiró, Muehlmann Luis Alexandre
Faculty of Ceilandia, University of Brasilia, Brasilia 72220-275, Brazil.
Laboratory of Nanobiotechnology, Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia, Brasilia 70910-900, Brazil.
Pharmaceutics. 2022 Jul 27;14(8):1564. doi: 10.3390/pharmaceutics14081564.
Immunogenic cell death (ICD) is a modality of regulated cell death that is sufficient to promote an adaptive immune response against antigens of the dying cell in an immunocompetent host. An important characteristic of ICD is the release and exposure of damage-associated molecular patterns, which are potent endogenous immune adjuvants. As the induction of ICD can be achieved with conventional cytotoxic agents, it represents a potential approach for the immunotherapy of cancer. Here, different aspects of ICD in cancer biology and treatment are reviewed.
免疫原性细胞死亡(ICD)是一种程序性细胞死亡方式,足以在免疫功能正常的宿主中促进针对死亡细胞抗原的适应性免疫反应。ICD的一个重要特征是损伤相关分子模式的释放和暴露,这些是强大的内源性免疫佐剂。由于传统细胞毒性药物可诱导ICD,它代表了一种癌症免疫治疗的潜在方法。本文综述了ICD在癌症生物学和治疗中的不同方面。